Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7715 pages
Showing 2251 - 2300Excess Cardiovascular Disease Risk in Patients With Early-Stage Lymphoma: Personalizing Radiotherapy Delivery
As reported in the Journal of Clinical Oncology by Cutter et al, an analysis from the UK NCRI RAPID trial of positron-emission tomography (PET)-directed therapy in patients with early-stage Hodgkin lymphoma indicated that the use of involved-field radiotherapy in PET-negative patients who had...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...
Cetuximab Plus Avelumab as Rechallenge Therapy for RAS Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial reported in JAMA Oncology, Martinelli et al found that cetuximab rechallenge plus avelumab showed activity and was well tolerated in patients with RAS wild-type metastatic colorectal cancer who had responded to first-line chemotherapy plus an anti-EGFR agent and then...
First-Line Cisplatin Plus Gemcitabine or Fluorouracil for Advanced Nasopharyngeal Carcinoma: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Hong et al, the final overall survival analysis of the Chinese phase III GEM20110714 trial showed a significant benefit with gemcitabine/cisplatin vs fluorouracil/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal...
Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL
In a Chinese single-institution phase I study reported in the Journal of Clinical Oncology, Pan et al found that donor-derived CD7 chimeric antigen receptor (CAR) T-cell therapy produced a high complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia...
Talazoparib in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Repair Gene Alterations
In the phase II TALAPRO-1 trial reported in The Lancet Oncology, Johann S. de Bono, PhD, and colleagues found that monotherapy with the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib produced durable responses in patients with metastatic castration-resistant prostate cancer and DNA...
Does Sparing the Hippocampus During Prophylactic Cranial Irradiation for SCLC Help to Preserve Cognitive Function?
In the Spanish phase III PREMER trial reported in the Journal of Clinical Oncology, Rodríguez de Dios et al found that hippocampal avoidance during prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) was associated with better preservation of cognitive function vs PCI alone and ...
Simulation Model–Based Clinical Decision Tool for Predicting Benefit of Adjuvant Chemoendocrine vs Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
As reported in the Journal of Clinical Oncology, Jayasekera et al have developed a clinical decision tool called BTxChoice that can be used with or without the 21-gene recurrence score to estimate the potential benefit of adjuvant chemoendocrine vs endocrine therapy in women with node-negative,...
Hypofractionated Image-Guided vs Conventional Radiotherapy in Patients With Stage II/III NSCLC Ineligible for Concurrent Chemoradiation
In a phase III trial reported in JAMA Oncology, Puneeth Iyengar, MD, PhD, and colleagues found that accelerated hypofractionated image-guided radiotherapy (IGRT) did not improve 1-year overall survival vs conventional radiotherapy in patients with stage II/III non–small cell lung cancer (NSCLC) who ...
Addition of Entinostat to Exemestane in Aromatase Inhibitor–Resistant, HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MB, BCh, MD, and colleagues, the phase III ECOG-ACRIN Cancer Research Group E2112 trial showed no significant improvement in progression-free or overall survival with the addition of the histone deacetylase inhibitor entinostat...
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
In a phase I trial (MajesTEC-1) reported in The Lancet, Saad Z. Usmani, MD, FACP, and colleagues found that the B-cell maturation antigen (BCMA)-CD3 bispecific antibody teclistamab produced a high rate of durable responses at the recommended phase II dose in patients with relapsed or refractory...
Genomic-Adjusted Radiation Dose Model to Predict Radiotherapy Benefit Across Cancer Types
In a study reported in The Lancet Oncology, Scott et al found that application of the genomic-adjusted radiation dose (GARD) model to cohorts of patients with different types of cancer showed a significant association of GARD with benefit of radiotherapy. As stated by the investigators, “We...
VOYAGER Trial: Avapritinib vs Regorafenib in Molecularly Unselected Previously Treated Advanced GIST
As reported in the Journal of Clinical Oncology by Yoon-Koo Kang, MD, and colleagues, the phase III VOYAGER trial showed no improvement in progression-free survival with avapritinib vs regorafenib as third- or later-line treatment of patients with molecularly unselected, locally advanced,...
Seroconversion After COVID-19 Vaccination in Adult Patients With Hematologic Malignancies
In a single-institution retrospective study reported in a research letter in JAMA Oncology, Ollila et al found a low rate of seroconversion after COVID-19 vaccination among adult patients with hematologic malignancies. Study Details The study included 160 patients at Rhode Island Hospital receiving ...
Meta-analysis of Outcomes With the Addition of Adjuvant Trastuzumab to Chemotherapy for HER2-Positive Breast Cancer
In a study conducted by the Early Breast Cancer Trialists’ Collaborative Group and reported in The Lancet Oncology by Bradley et al, an individual patient data meta-analysis of randomized trials has shown that the addition of adjuvant trastuzumab to chemotherapy reduces the risk of disease...
Financial Toxicity Associated With Atherosclerotic Cardiovascular Disease and Cancer
In a study of National Health Interview Survey (NHIS) data reported in JACC: CardioOncology, Valero-Elizondo et al found that U.S. adult patients with atherosclerotic cardiovascular disease (ASCVD) were at greater risk of financial toxicity than those with cancer alone, with risk being the greatest ...
Causes of Death Among Men Diagnosed With Metastatic Prostate Cancer
In a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) data reported in JAMA Network Open, Elmehrath et al found that a substantial proportion of men diagnosed with metastatic prostate cancer between 2000 and 2016 in the United States died from causes unrelated to...
Vincristine/Irinotecan With or Without Temozolomide for Relapsed or Refractory Rhabdomyosarcoma
In a European phase II trial (VIT-0910) reported in the Journal of Clinical Oncology, Defachelles et al found that the combination of vincristine/irinotecan with vs without temozolomide produced better outcomes—albeit with increased toxicity—in children and adults with relapsed or refractory...
Amivantamab for Patients With EGFR Exon 20 Insertion–Mutated NSCLC After Disease Progression on Platinum Therapy
As reported in the Journal of Clinical Oncology by Keunchil Park, MD, PhD, and colleagues, amivantamab-vmjw given at the selected phase II dose in a phase I trial (CHRYSALIS) produced durable responses in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer (NSCLC) whose disease...
Effect of Regionalization of Gastric Cancer Care in an Integrated Health-Care System
In a retrospective cohort study reported in the Journal of Clinical Oncology, Teh et al found that regionalization of gastric cancer care in a U.S. integrated health-care system resulted in the increased use of laparoscopic gastrectomy and D2 lymphadenectomy, as well as improved overall survival...
Evaluation of Baseline Cancer Mortality Risk in Medicaid Expansion and Nonexpansion States
In a study of National Cancer Database data reported in a research letter in JAMA Oncology, Salazar et al found little difference in baseline cancer mortality rates between U.S. states that expanded Medicaid enrollment and nonexpansion states prior to expansion in 2009 and immediately following...
Risk of Early Cardiac Toxicity With Posttransplantation Cyclophosphamide After HSCT
In a French single-center retrospective cohort study reported in JACC: CardioOncology, Duléry et al found that posttransplantation cyclophosphamide was associated with a significantly increased risk of early cardiac events among patients receiving allogeneic hematopoietic stem cell transplantation...
Addition of Avelumab to Chemotherapy in Previously Untreated Patients With Advanced Epithelial Ovarian Cancer: JAVELIN Ovarian 100 Trial
As reported by Bradley J. Monk, MD, and colleagues in The Lancet Oncology, the phase III JAVELIN Ovarian 100 trial showed no progression-free survival benefit with the addition of concurrent and/or maintenance avelumab to chemotherapy in previously untreated patients with advanced epithelial...
Ribociclib Plus Topotecan/Temozolomide or Everolimus in Pediatric Patients With Advanced Cancer Enriched for Target Pathway Alterations
In a European platform trial (AcSé-ESMART) reported in the Journal of Clinical Oncology, Bautista et al found evidence of activity of the CDK4/6 inhibitor ribociclib plus the mTOR inhibitor everolimus in a population of children with recurrent or refractory malignancies enriched for alterations in...
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
On June 30, 2021, asparaginase erwinia chrysanthemi (recombinant)-rywn was approved as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed...
No Progression-Free Survival Benefit With First-Line Avelumab Plus Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
As reported in The Lancet Oncology by Nancy Y. Lee, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III JAVELIN Head and Neck 100 trial has shown no improvement in progression-free survival with the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy in patients...
Mortality Risk With Adjuvant vs Early Salvage Radiotherapy in Men With Adverse Pathology at Radical Prostatectomy for Prostate Cancer
In a retrospective cohort study reported in the Journal of Clinical Oncology, Derya Tilki, MD, of Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf, Hamburg, and colleagues found that adjuvant radiotherapy was associated with reduced risk for all-cause mortality vs early...
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo...
S-1 Chemoradiation vs Radiotherapy Alone in Patients Aged 70 to 85 With Esophageal Cancer
In a Chinese phase III trial reported in JAMA Oncology, Ji et al found that concurrent chemoradiation with S-1 was associated with improved overall survival and acceptable toxicity vs radiotherapy alone in older patients with esophageal cancer. As stated by the investigators, “Most older patients ...
Pertuzumab and Trastuzumab in Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
As reported in The Lancet Oncology by Milind Javle, MD, and colleagues, findings in a cohort of the phase IIa MyPathway multiple basket study showed that the combination of pertuzumab and trastuzumab produced responses in some previously treated patients with HER2-positive metastatic biliary tract...
Minimally Invasive Esophagectomy Followed by Intrathoracic vs Cervical Anastomosis for Esophageal Cancer
In a Dutch trial reported in JAMA Surgery, van Workum and colleagues found that intrathoracic anastomosis following total or hybrid minimally invasive esophagectomy for esophageal cancer was associated with significantly reduced risk of anastomotic leakage requiring intervention and other...
NRG-LU001 Trial: Addition of Metformin to Chemoradiation in Locally Advanced NSCLC
In the phase II NRG-LU001 trial reported in JAMA Oncology, Skinner et al found that the addition of metformin to concurrent chemoradiation did not improve progression-free survival or overall survival at 1 year in patients with unresectable stage III non–small cell lung cancer (NSCLC). Study...
Comparison of I-131 Metaiodobenzylguanidine–Containing Regimens in Relapsed or Refractory Neuroblastoma
In a phase II New Approaches to Neuroblastoma Therapy (NANT) consortium study reported in the Journal of Clinical Oncology, DuBois et al found that combining the radiotherapeutic I-131 metaiodobenzylguanidine (MIBG) with vorinostat produced a higher response rate in relapsed or refractory...
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported inThe New England Journal of Medicine by Dean F. Bajorin, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo...
Adding Short-Term Androgen Suppression to Radiotherapy for Patients With Localized Intermediate-Risk Prostate Cancer: Long-Term Findings
As reported in the Journal of Clinical Oncology by Bolla et al, a 12-year analysis among patients with localized intermediate-risk prostate cancer in the EORTC 22991 trial showed improved event-free and disease-free survival with the addition of 6 months of concomitant and adjuvant androgen...
ELEVATE-RR Trial: Acalabrutinib vs Ibrutinib in Previously Treated Patients With CLL
As reported in the Journal of Clinical Oncology by John C. Byrd, MD, and colleagues, the phase III ELEVATE-RR trial has shown noninferior progression-free survival with the more selective Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib vs the less selective inhibitor ibrutinib in previously...
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer
In a phase III trial reported in The New England Journal of Medicine, Michael Gnant, MD, and colleagues found no difference in disease-free survival with 2 vs 5 years of treatment with the aromatase inhibitor anastrozole in postmenopausal women with early hormone receptor (HR)-positive breast...
Does Pain Affect the Employment and Financial Outcomes of Cancer Survivors?
In a study reported in the Journal of Clinical Oncology, Halpern et al found that cancer survivors with pain had worse employment and financial outcomes than did those reporting no pain. Study Details The study used data from 1,213 adult survivors identified from the 2016–2017 Medical Expenditure...
Revised Children’s Oncology Group Neuroblastoma Risk Classification System
As reported in the Journal of Clinical Oncology by Irwin et al, the Children’s Oncology Group (COG) has developed a new neuroblastoma risk classification (COG version 2) that uses the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporates segmental chromosome aberrations as ...
Second-Generation Androgen Receptor Inhibitors for Older Men With Nonmetastatic Castration-Resistant Prostate Cancer
In a U.S. Food and Drug Administration pooled analysis of clinical trial patient-level data reported in The Lancet Oncology, Fallah et al found that second-generation androgen receptor inhibitor treatment was associated with survival benefits in patients aged 80 years or older with nonmetastatic...
Pulsed Vincristine/Dexamethasone Maintenance in Pediatric Acute Lymphoblastic Leukemia
In a Chinese phase III trial (CCCG-ALL-2015) reported in The Lancet Oncology, Yang et al found that 1 year of maintenance therapy with pulsed vincristine and dexamethasone was noninferior to 2 years in low-risk pediatric patients with acute lymphoblastic leukemia and was borderline inferior in...
Tremelimumab, Durvalumab, or Both in Unresectable Hepatocellular Carcinoma
In a randomized expansion phase of a phase I/II study reported in the Journal of Clinical Oncology, Robin Kate Kelley, MD, and colleagues found that a novel regimen consisting of a single priming dose of tremelimumab in combination with durvalumab was associated with good outcomes in patients with...
Addition of Metformin to Chemoradiotherapy for Locally Advanced NSCLC
As reported in JAMA Oncology by Tsakiridis et al, the Canadian phase II OCOG-ALMERA trial, which was closed early due to slow accrual, showed that the addition of metformin to chemoradiation therapy was associated with worse outcomes in patients with unresected locally advanced non–small cell lung ...
Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers
In an Israeli single-institution prospective cohort study reported in The New England Journal of Medicine, Bergwerk et al identified breakthrough COVID-19 infections among 39 of 1,497 health-care workers fully vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine. As stated by the investigators:...
Impact of Nurse Navigation Program on Outcomes in Minority Patients With Aggressive Lymphoma
In a single-institution study reported in the journal Cancer, Hu et al found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities in care and outcomes between minority patients and White patients with aggressive large B-cell lymphoma (LBCL). As...
Continuous Azacitidine vs Reduced-Intensity Conditioning HSCT in Older Patients With Advanced Myelodysplastic Syndrome
In the German phase II VidazaAllo study reported in the Journal of Clinical Oncology, Kröger et al found that switching from azacitidine to reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (HSCT) contingent upon donor availability was associated with better outcomes ...
Carboplatin Intensification for the Treatment of Pediatric High-Risk Medulloblastoma
In a Children’s Oncology Group (COG) phase III trial reported in JAMA Oncology, Leary et al found that the addition of carboplatin to radiotherapy in pediatric patients with newly diagnosed high-risk medulloblastoma improved event-free survival in the group 3 molecular subgroup but not in others....
Incidence of Axillary Adenopathy in Screening or Diagnostic Mammography After COVID-19 Vaccination
In a single-center retrospective study reported in a research letter in JAMA Oncology, Robinson et al found a vaccine-related axillary adenopathy incidence rate of 3% among women undergoing screening or diagnostic mammography within 90 days of receipt of at least one dose of a COVID-19 vaccine....
Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors
In a prospective study from the St. Jude Lifetime Cohort reported in the Journal of Clinical Oncology, Williams et al found that prefrailty and frailty among young adult childhood cancer survivors were associated with neurocognitive decline vs nonfrail counterparts, mirroring the association...
